IIH
MCID: INT303
MIFTS: 56

Intracranial Hypertension, Idiopathic (IIH)

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intracranial Hypertension, Idiopathic

MalaCards integrated aliases for Intracranial Hypertension, Idiopathic:

Name: Intracranial Hypertension, Idiopathic 57 20
Pseudotumor Cerebri 57 12 73 20 53 58 54 44 15 17 70
Benign Intracranial Hypertension 12 53 58 32
Idiopathic Intracranial Hypertension 12 20 58
Iih 20 58
Benign Intracran. Hypt. 12

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal recessive


HPO:

31
intracranial hypertension, idiopathic:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Intracranial Hypertension, Idiopathic

GARD : 20 Idiopathic intracranial hypertension (IIH), formerly known as pseudotumor cerebri, is a condition that affects the brain. Pseudotumor cerebri literally translates to "false brain tumor." This term was used because symptoms of IIH resemble those of brain tumors depsite no tumor being present. Symptoms of IIH may include severe headache, nausea and vomiting, altered vision, and pulsating sounds within the head. A person with IIH may also have symptoms such as a stiff neck, back or arm pain, eye pain, and memory problems. If the condition remains untreated, permanent visual loss or blindness may develop. While the exact underlying cause of IIH is not known (idiopathic), it is likely due to high fluid pressure within the skull that is due to buildup, or poor absorption, of cerebrospinal fluid (CSF). IIH most often (but not always) occurs in young, overweight, females. When symptoms of intracranial pressure have an identifiable cause such as another underlying disease or medication, the condition is instead referred to as secondary IH. Treatment for IIH may include medications called carbonic anhydrase inhibitors to control the production of CSF. In some cases, weight loss may also be recommended. However, medications and/or weight loss are not effective in all cases. In severe cases that do not respond to medication and weight loss, surgery may be needed to relieve symptoms and/or preserve vision.

MalaCards based summary : Intracranial Hypertension, Idiopathic, also known as pseudotumor cerebri, is related to intracranial hypertension and acne, and has symptoms including neurologic symptoms An important gene associated with Intracranial Hypertension, Idiopathic is SSTR1 (Somatostatin Receptor 1), and among its related pathways/superpathways are Metabolism and Spinal Cord Injury. The drugs Lymecycline and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and pituitary, and related phenotypes are increased intracranial pressure and obesity

NINDS : 53 Pseudotumor cerebri literally means "false brain tumor." It is likely due to high pressure within the skull caused by the buildup or poor absorption of cerebrospinal fluid (CSF). The disorder is most common in women between the ages of 20 and 50. Symptoms of pseudotumor cerebri, which include headache, nausea, vomiting, and pulsating sounds within the head, closely mimic symptoms of large brain tumors.

Wikipedia : 73 Idiopathic intracranial hypertension (IIH), previously known as pseudotumor cerebri and benign... more...

More information from OMIM: 243200

Related Diseases for Intracranial Hypertension, Idiopathic

Diseases related to Intracranial Hypertension, Idiopathic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
# Related Disease Score Top Affiliating Genes
1 intracranial hypertension 31.7 SLC12A3 RBP4 HSD11B1 F2 AQP4 AQP1
2 acne 30.8 RBP4 POMC IGF1
3 hydrocephalus 30.6 PTGDS IGF1 AQP4 AQP1
4 cranial nerve palsy 30.6 POMC AQP4
5 abducens nerve disease 30.6 POMC F2 AQP4
6 communicating hydrocephalus 30.4 PTGDS AQP4 AQP1
7 branch retinal artery occlusion 30.4 F2 AQP4
8 hyperthyroidism 30.3 POMC LEP IGF1
9 traumatic brain injury 30.3 IGF1 AQP4
10 intracranial hypotension 30.3 PTGDS F2
11 intraocular pressure quantitative trait locus 30.3 CA2 AQP4 AQP1
12 leptin deficiency or dysfunction 30.2 RBP4 POMC LEP IGF1
13 fibromyalgia 30.1 POMC LEP IGF1
14 keratomalacia 30.0 RBP4 RARA
15 central precocious puberty 30.0 LEP IGF1
16 pituitary gland disease 30.0 SSTR1 POMC IGF1
17 sleep disorder 30.0 POMC OPN4 LEP IGF1
18 pituitary adenoma, prolactin-secreting 30.0 SSTR1 POMC IGF1
19 hyperandrogenism 29.9 POMC IGF1 HSD11B1
20 migraine with or without aura 1 29.9 POMC OPN4 LEP F2
21 amenorrhea 29.9 POMC LEP IGF1
22 renal tubular acidosis 29.9 CA2 CA14 CA1
23 normal pressure hydrocephalus 29.8 PTGDS IGF1 AQP4
24 hypopituitarism 29.7 POMC LEP IGF1 HSD11B1
25 metabolic acidosis 29.7 IGF1 F2 CA2
26 pituitary apoplexy 29.5 POMC IGF1
27 conn's syndrome 29.4 SLC12A3 POMC LEP IGF1 HSD11B1
28 congenital disorder of glycosylation, type iih 11.6
29 empty sella syndrome 11.2
30 galactosemia ii 11.2
31 papilledema 11.1
32 idiopathic infantile hypercalcemia 11.0
33 headache 10.7
34 yemenite deaf-blind hypopigmentation syndrome 10.5
35 acute promyelocytic leukemia 10.5
36 3-methylglutaconic aciduria, type iii 10.5
37 hypothyroidism 10.5
38 systemic lupus erythematosus 10.4
39 hypervitaminosis a 10.4
40 thrombosis 10.4
41 lyme disease 10.4
42 lupus erythematosus 10.4
43 spontaneous intracranial hypotension 10.4
44 subependymoma 10.4 AQP4 AQP1
45 ifap syndrome 2 10.4
46 deficiency anemia 10.4
47 dysferlinopathy 10.3 AQP4 AQP1
48 chiari malformation 10.3
49 arachnoiditis 10.3 POMC AQP4
50 xeroderma pigmentosum, variant type 10.3

Comorbidity relations with Intracranial Hypertension, Idiopathic via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Intracranial Hypertension, Idiopathic:



Diseases related to Intracranial Hypertension, Idiopathic

Symptoms & Phenotypes for Intracranial Hypertension, Idiopathic

Human phenotypes related to Intracranial Hypertension, Idiopathic:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 increased intracranial pressure 58 31 hallmark (90%) Very frequent (99-80%) HP:0002516
2 obesity 58 31 frequent (33%) Frequent (79-30%) HP:0001513
3 papilledema 58 31 frequent (33%) Frequent (79-30%) HP:0001085
4 allergy 58 31 frequent (33%) Frequent (79-30%) HP:0012393
5 sleep disturbance 58 31 occasional (7.5%) Occasional (29-5%) HP:0002360
6 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
7 photophobia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000613
8 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
9 visual loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0000572
10 abnormal emotion/affect behavior 58 31 occasional (7.5%) Occasional (29-5%) HP:0100851
11 blurred vision 58 31 occasional (7.5%) Occasional (29-5%) HP:0000622
12 scintillating scotoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0010822
13 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
14 depressivity 58 31 very rare (1%) Very rare (<4-1%) HP:0000716
15 back pain 58 31 very rare (1%) Very rare (<4-1%) HP:0003418
16 vertigo 58 31 very rare (1%) Very rare (<4-1%) HP:0002321
17 migraine 58 31 very rare (1%) Very rare (<4-1%) HP:0002076
18 lethargy 58 31 very rare (1%) Very rare (<4-1%) HP:0001254
19 pulsatile tinnitus 58 31 very rare (1%) Very rare (<4-1%) HP:0008629
20 focal sensory seizure with olfactory features 31 very rare (1%) HP:0011161
21 hypertension 31 HP:0000822
22 headache 58 Very frequent (99-80%)
23 olfactory auras 58 Very rare (<4-1%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
H E E N T:
papilledema
pseudotumor cerebri
idiopathic intracranial hypertension

Clinical features from OMIM®:

243200 (Updated 20-May-2021)

UMLS symptoms related to Intracranial Hypertension, Idiopathic:


neurologic symptoms

GenomeRNAi Phenotypes related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.15 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.15 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.15 RARA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-107 10.15 ALG6
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.15 ALG6
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.15 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-135 10.15 SSTR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.15 ALG6
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.15 ALG6
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.15 IGF1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.15 IGF1 RARA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 10.15 F2 SSTR1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 10.15 F2 SSTR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.15 SSTR1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.15 ALG6
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.15 SSTR1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.15 IGF1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.15 ALG6
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 10.15 IGF1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.15 IGF1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.15 ALG6
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.15 IGF1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 10.15 RARA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 10.15 SSTR1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.15 ALG6 RARA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 10.15 SSTR1
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.15 IGF1
28 Decreased viability GR00240-S-1 9.64 RARA
29 Decreased viability GR00249-S 9.64 CA2 CA7 OPN4 RBP4 SLC12A3
30 Decreased viability GR00381-A-1 9.64 AQP1 OPN4 RARA RBP4
31 Decreased viability GR00381-A-2 9.64 RBP4
32 Decreased viability GR00381-A-3 9.64 OPN4 RBP4
33 Decreased viability GR00386-A-1 9.64 ALG6 CA13 POMC RARA
34 Decreased viability GR00402-S-2 9.64 AQP1 CA14 RARA SLC12A3

MGI Mouse Phenotypes related to Intracranial Hypertension, Idiopathic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 AQP1 AQP4 CA14 CA2 CA5B CA7
2 endocrine/exocrine gland MP:0005379 10.14 AQP1 AQP4 CA2 F2 HSD11B1 IGF1
3 cardiovascular system MP:0005385 10.13 AQP1 AQP4 F2 HSD11B1 IGF1 LEP
4 nervous system MP:0003631 10.1 AQP1 AQP4 CA2 CA7 F2 HSD11B1
5 immune system MP:0005387 10.06 ALG6 AQP1 AQP4 CA2 F2 HSD11B1
6 renal/urinary system MP:0005367 9.85 ALG6 AQP1 AQP4 CA2 IGF1 LEP
7 respiratory system MP:0005388 9.56 AQP1 AQP4 CA2 F2 HSD11B1 IGF1
8 vision/eye MP:0005391 9.28 AQP1 AQP4 CA13 CA14 LEP OPN4

Drugs & Therapeutics for Intracranial Hypertension, Idiopathic

Drugs for Intracranial Hypertension, Idiopathic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
2
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
3
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
4
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
5
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
6
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
7
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
8
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
9
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 2, Phase 3 14838-15-4 26934
10
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
11
Acetazolamide Approved, Vet_approved Phase 3 59-66-5 1986
12 Respiratory System Agents Phase 2, Phase 3
13 Fibrinolytic Agents Phase 2, Phase 3
14 Narcotics Phase 2, Phase 3
15 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
16 Antirheumatic Agents Phase 2, Phase 3
17 Anti-Inflammatory Agents Phase 2, Phase 3
18 Analgesics Phase 2, Phase 3
19 Antitussive Agents Phase 2, Phase 3
20 Cyclooxygenase Inhibitors Phase 2, Phase 3
21 Platelet Aggregation Inhibitors Phase 2, Phase 3
22 Analgesics, Opioid Phase 2, Phase 3
23 Antipyretics Phase 2, Phase 3
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
25 Analgesics, Non-Narcotic Phase 2, Phase 3
26 Anticonvulsants Phase 3
27 diuretics Phase 3
28 Carbonic Anhydrase Inhibitors Phase 3
29
Heparin Approved, Investigational 9005-49-6 772 9812414
30
Dalteparin Approved Early Phase 1 9005-49-6
31
Tinzaparin Approved Early Phase 1 9041-08-1, 9005-49-6 25244225
32
Aspirin Approved, Vet_approved 50-78-2 2244
33
Clopidogrel Approved 120202-66-6, 113665-84-2 60606
34 calcium heparin
35 Anticoagulants Early Phase 1
36 Fibrin fragment D Early Phase 1
37 Heparin, Low-Molecular-Weight Early Phase 1
38 Hemostatics
39 Anti-Bacterial Agents
40 Antibiotics, Antitubercular
41 Anesthetics

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
2 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
3 Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss Terminated NCT03501966 Phase 3 Acetazolamide
4 Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study. Completed NCT02017444 Phase 2 AZD4017
5 Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy Completed NCT01407809 Phase 1
6 Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension Unknown status NCT02143258
7 Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension Unknown status NCT02394067
8 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858
9 Comparison of Optic Nerve Sheath Diameters Measured by Optic Ultrasonography Before and After Lumbar Puncture in Idiopathic Intracranial Hypertension Patients Completed NCT04603118
10 Prospective Measurement of Blood Pressure and End Tidal Carbon Dioxide Content Effects on Venous Sinus Caliber and Pressures in Patients With Idiopathic Intracranial Hypertension Undergoing Stenting Completed NCT03867461
11 D-dimer and the Use of Anticoagulation in IIH Completed NCT03963336 Early Phase 1 LMWH;acetazolamide
12 The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study Completed NCT00071903
13 Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension Recruiting NCT03556085
14 Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension Recruiting NCT04032379
15 Assessment of Raised Intracranial Pressure in Patients With Idiopathic Intracranial Hypertension by Optic Nerve Sheath Diameter and Transcranial Doppler Measurements Recruiting NCT04314128
16 Assessment of Venous Drainage in Idiopathic Intracranial Hypertension Recruiting NCT04115553
17 Assessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Pseudotumor Cerebri Recruiting NCT04309383
18 Assessment of Pupillary Response and Visual Field Defects by Objective Multifocal Chromatic Pupillometer in Patients With Pseudotumor Cerebri and Healthy Subjects Recruiting NCT03304314
19 Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP) Recruiting NCT02513914
20 Post-Market Clinical Follow-up Registry of Patients With CODMAN CERTAS Plus Programmable Valves Recruiting NCT04207229
21 A Randomised Controlled Trial of Bariatric Surgery Versus a Community Weight Loss Programme for the Sustained Treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial Active, not recruiting NCT02124486
22 Evaluating Raised Intracranial Pressure Using MR Elastography Active, not recruiting NCT03096743
23 Astronaut Vision Issues and One Carbon Metabolism: Expanded Polymorphism Evaluation and Evaluation in a Potential Analog Population Active, not recruiting NCT02896452
24 An Open-Label, Parallel, Randomized Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures, Using a Handheld Tactile Imaging-based Method Versus Palpation Not yet recruiting NCT04796935
25 The Potential Value of Axial Length and Central Corneal Thickness in the Assessment for Risk of Permanent Optic Nerve Damage and Visual Field Loss in Benign Intracranial Hypertension Terminated NCT02541994
26 Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement: Continuous Intracranial Pressure Monitoring Subprotocol Terminated NCT01863381
27 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Intracranial Hypertension, Idiopathic

Cochrane evidence based reviews: pseudotumor cerebri

Genetic Tests for Intracranial Hypertension, Idiopathic

Anatomical Context for Intracranial Hypertension, Idiopathic

MalaCards organs/tissues related to Intracranial Hypertension, Idiopathic:

40
Brain, Eye, Pituitary, Thyroid, Heart, Kidney, Myeloid

Publications for Intracranial Hypertension, Idiopathic

Articles related to Intracranial Hypertension, Idiopathic:

(show top 50) (show all 1367)
# Title Authors PMID Year
1
Expression of somatostatin receptors 1 and 2 in human choroid plexus and arachnoid granulations: implications for idiopathic intracranial hypertension. 54 57
12427069 2002
2
A familial coincidence of pseudotumor cerebri and communicating hydrocephalus. 57 61
1876253 1991
3
Pseudotumor cerebri. Report of a familial occurrence. 57 61
4808492 1974
4
Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension. 57
12402264 2002
5
Familial benign intracranial hypertension. 57
932759 1976
6
Papilledema and idiopathic intracranial hypertension. 57
5775633 1969
7
Assessment of Pediatric Pseudotumor Cerebri Clinical Characteristics and Outcomes. 61
33148096 2021
8
Coronavirus Infections in the Nervous System of Children: A Scoping Review Making the Case for Long-Term Neurodevelopmental Surveillance. 61
33676141 2021
9
Doxycycline-induced idiopathic intracranial hypertension in a patient with Lyme disease. 61
33600108 2021
10
Increased Intracranial Pressure Without Hydrocephalus Associated With Spinal Cord Tumor: Literature Review. 61
32826715 2021
11
Idiopathic intracranial hypertension with optic nerve edema - treatment options, case report. 61
33754595 2021
12
Pseudotumor Cerebri with Blindness. 61
33717740 2021
13
Pseudotumor cerebri syndrome in a child with Alagille syndrome: intracranial pressure dynamics and treatment outcome after ventriculoperitoneal shunting. 61
33555437 2021
14
Adverse Reactions Induced by Minocycline: A Review of Literature. 61
33494681 2021
15
Prepontine Shunting for Pseudotumor Cerebri in Previously Failed Shunt Patients: A 5-Year Analysis. 61
33037814 2021
16
Murine typhus presenting as pseudotumor cerebri. 61
33529597 2021
17
Case Report: Successful Treatment of Cutaneous Squamous Cell Carcinoma in Three Patients With a Combination of Acitretin and Clarithromycin. 61
33718249 2021
18
Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. 61
33440683 2021
19
Acute adrenal insufficiency due to paracoccidiodomycosis. Report of 2 cases. 61
32874849 2020
20
Pseudotumor cerebri syndrome with different types of hormonal contraceptives in women of child-bearing age. 61
32810878 2020
21
Diagnosing Pseudotumor Cerebri: An Age-based Approach. 61
33354101 2020
22
Trends in the Surgical Treatment of Pseudotumor Cerebri Syndrome in the United States. 61
33320265 2020
23
Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty. 61
33292495 2020
24
Pseudotumor cerebri syndrome causing a terson like syndrome. 61
33305067 2020
25
A Comparison Between the Clinical Features of Pseudotumor Cerebri Secondary to Tetracyclines and Idiopathic Intracranial Hypertension. 61
32738227 2020
26
Optic nerve sheath decompression saves sight in severe papilloedema: results from 81 eyes in 56 patients with pseudotumor cerebri. 61
33377617 2020
27
Intracranial hypertension due to spinal cord tumor misdiagnosed as pseudotumor cerebri syndrome: case report. 61
33213405 2020
28
Rare Presentation of Pseudotumor Cerebri in a Pediatric Patient With Granulomatosis With Polyangiitis. 61
33364094 2020
29
Pseudotumor Cerebri in Young Children: Is It Different From Adults? 61
32600089 2020
30
Pseudotumor Cerebri Syndrome in Young Children: What Is the Difference From Adults? 61
32631123 2020
31
Unilateral papilledema in idiopathic intracranial hypertension: A rare entity. 61
33143486 2020
32
More than meets the eye: Papilledema from syphilis posing as idiopathic intracranial hypertension. 61
32753004 2020
33
Prevalence of Adrenal Insufficiency and Glucocorticoid Use in Pediatric Pseudotumor Cerebri Syndrome. 61
33110007 2020
34
Growth Hormone Treatment and Papilledema: a Prospective Pilot Study. 61
33006547 2020
35
Risk factors for central retinal vein occlusion in young adults. 61
33008264 2020
36
Association of Adrenal Insufficiency With Pediatric Pseudotumor Cerebri Syndrome. 61
32940641 2020
37
Lower thoracic schwannoma presenting as pseudotumor cerebri: a case report. 61
32924621 2020
38
Pseudotumor cerebri syndrome and essential thrombocythaemia: Case report and literature review. 61
32682124 2020
39
Role of Imaging in pseudotumor cerebri syndrome. 61
32736880 2020
40
Optic Nerve Sheath Diameter and Retinal Artery Resistive Index Measurements with Bedside Ophthalmic Ultrasound in Pediatric Patients with Pseudotumor Cerebri Syndrome. 61
32685245 2020
41
Acetazolamide-Induced Agranulocytosis in a Patient with Pseudotumor Cerebri. 61
33623291 2020
42
Quetiapine-Associated Pseudotumor Cerebri. 61
31356344 2020
43
Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis mimicking pseudotumor cerebri: A case report. 61
32147202 2020
44
The Use of Endoscopic Third Ventriculostomy as Treatment for Idiopathic Intracranial Hypertension: Case Report and a Review of Previously Reported Cases. 61
32634635 2020
45
C1 Transverse Process Resection for Management of Jugular Stenosis. 61
32181484 2020
46
Vitamin B12 Deficiency: An Association or Etiology of Pseudotumor Cerebri in An Infant. 61
32036594 2020
47
Pseudotumor cerebri syndrome associated with MIS-C: a case report. 61
32795406 2020
48
Prevalence of Signs and Symptoms of Pseudotumor Cerebri Syndrome Before and After Transsphenoidal Surgery for Cushing's Disease - A Prospective Consecutive Case Series. 61
32722820 2020
49
Pseudotumor cerebri in a transgender woman: case report and literature review. 61
31879065 2020
50
Fulminant Pseudotumor Cerebri Syndrome Secondary to Over-the-Counter Topical Retinoids. 61
31609833 2020

Variations for Intracranial Hypertension, Idiopathic

Expression for Intracranial Hypertension, Idiopathic

Search GEO for disease gene expression data for Intracranial Hypertension, Idiopathic.

Pathways for Intracranial Hypertension, Idiopathic

Pathways related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 RBP4 PTGDS POMC HSD11B1 CA7 CA5B
2 11.58 LEP AQP4 AQP1
3 11.39 CA2 AQP4 AQP1
4
Show member pathways
10.68 CA2 CA1 AQP1
5 10.67 POMC LEP
6
Show member pathways
10.56 CA7 CA5B CA2 CA14 CA13 CA1

GO Terms for Intracranial Hypertension, Idiopathic

Biological processes related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.71 RBP4 RARA LEP
2 glucose homeostasis GO:0042593 9.69 RBP4 POMC LEP
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 LEP IGF1 F2
4 negative regulation of tumor necrosis factor production GO:0032720 9.61 RARA POMC IGF1
5 cell volume homeostasis GO:0006884 9.52 SLC12A3 AQP1
6 water transport GO:0006833 9.49 AQP4 AQP1
7 multicellular organismal water homeostasis GO:0050891 9.46 AQP4 AQP1
8 one-carbon metabolic process GO:0006730 9.43 CA7 CA5B CA2 CA14 CA13 CA1
9 negative regulation of cartilage development GO:0061037 9.4 RARA LEP
10 bone mineralization involved in bone maturation GO:0035630 9.37 LEP IGF1
11 cellular water homeostasis GO:0009992 9.32 AQP4 AQP1
12 carbon dioxide transport GO:0015670 9.26 CA2 AQP1
13 bicarbonate transport GO:0015701 9.17 CA7 CA5B CA2 CA14 CA13 CA1
14 positive regulation of cellular pH reduction GO:0032849 9.16 CA7 CA2

Molecular functions related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.8 RARA CA7 CA5B CA2 CA14 CA13
2 lyase activity GO:0016829 9.63 CA7 CA5B CA2 CA14 CA13 CA1
3 hormone activity GO:0005179 9.61 POMC LEP IGF1
4 hydro-lyase activity GO:0016836 9.43 CA7 CA5B CA2 CA14 CA13 CA1
5 water channel activity GO:0015250 9.4 AQP4 AQP1
6 retinoid binding GO:0005501 9.37 RBP4 PTGDS
7 arylesterase activity GO:0004064 9.32 CA2 CA1
8 carbonate dehydratase activity GO:0004089 9.1 CA7 CA5B CA2 CA14 CA13 CA1

Sources for Intracranial Hypertension, Idiopathic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....